journal article·2013-02

Folate-modified–chitosan-coated liposomes for tumor-targeted drug delivery

Kui Kun Yang, Ming Kong, Ya Nan Wei, Ya Liu, Xiao Jie Cheng, Jing Li, Hyun Jin Park, Xi Guang Chen

Journal of Materials Science· Volume 48· Issue 4
Publisher page

Abstract

In this study, a folate-modified–chitosan-coated liposome (FCCL) was prepared for tumor-targeted drug delivery. The folate–chitosan conjugates were characterized using 1H NMR and infrared spectrum analysis. The properties of folate–chitosan-coated liposomes (FCCLs) were studied and compared with those of traditional liposomes and chitosan-coated liposomes (CCLs). FCCLs were spherical in shape with a classic core–shell structure. Compared with conventional liposomes, FCCLs had larger size (average diameter: 182.0 nm), higher zeta potential (10.1 mV), prolonged drug release behaviors (55.76 % after 24 h), and better physical stability when stored at 25 °C, all similar to the properties of CCLs. With fluorescein as a model drug, fluorescein-loaded liposomes, CCLs, and FCCLs were prepared and their tumor targeting ability was evaluated according to the in vitro cellular uptake of fluorescein loaded nanoparticles by MCF-7 and HUVEC cells. Results demonstrated that FCCLs had a significant higher uptake by folate receptor positive cells (MCF-7) as compared to traditional liposomes and CCLs, which indicated that the FCCLs were promising nano-carriers for tumor-targeted drug delivery.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (46)

Show source-provided references
1. Bhosle J, Hall G (2009) Surgery (Oxford) 27:173. doi: 10.1016/j.mpsur.2009.01.00610.1016/j.mpsur.2009.01.006 ↗
2. Gómez-Hens A, Fernández-Romero JM (2006) Trends Anal Chem 25:167. doi: 10.1016/j.trac.2005.07.00610.1016/j.trac.2005.07.006 ↗
3. Coimbra M, Isacchi B, van Bloois L et al (2011) Int J Pharm 416:433. doi: 10.1016/j.ijpharm.2011.01.05610.1016/j.ijpharm.2011.01.056 ↗
4. Torchilin VP (2005) Nat Rev Drug Discov 4:14510.1038/nrd1632 ↗
5. Harrington KJ, Syrigos KN, Vile RG (2002) J Pharm Pharmacol 54:1573. doi: 10.1211/002235700224310.1211/0022357002243 ↗
6. Grit M, de Smidt JH, Struijke A, Crommelin DJA (1989) Int J Pharm 50:1. doi: 10.1016/0378-5173(89)90173-710.1016/0378-5173(89)90173-7 ↗
7. Graff A, Winterhalter M, Meier W (2001) Langmuir 17:919. doi: 10.1021/la001306m10.1021/la001306m ↗
8. Taylor TM, Davidson PM, Bruce BD, Weiss J (2005) Crit Rev Food Sci Nutr 45:58710.1080/10408390591001135 ↗
9. Zhang L, Granick S (2006) Nano Lett 6:69410.1021/nl052455y ↗
10. Mady MM, Darwish MM, Khalil S, Khalil WM (2009) Eur Biophys J 38:112710.1007/s00249-009-0524-z ↗
11. Henriksen I, Smistad G, Karlsen J (1994) Int J Pharm 101:227. doi: 10.1016/0378-5173(94)90218-610.1016/0378-5173(94)90218-6 ↗
12. Liang X, Wang H, Jiang X, Chang J (2010) J Nanopart Res 12:1723. doi: 10.1007/s11051-010-9896-310.1007/s11051-010-9896-3 ↗
13. Chen X-G, Liu C-S, Liu C-G, Meng X-H, Lee CM, Park H-J (2006) Biochem Eng J 27:269. doi: 10.1016/j.bej.2005.08.02110.1016/j.bej.2005.08.021 ↗
14. Ghosh A, Ali M (2012) J Mater Sci 47:1196. doi: 10.1007/s10853-011-5885-x10.1007/s10853-011-5885-x ↗
15. Liu W, Chen G, He G, He Z, Qian Z (2011) J Mater Sci 46:6758. doi: 10.1007/s10853-011-5632-310.1007/s10853-011-5632-3 ↗
16. Yin W, Su R, Qi W, He Z (2012) J Mater Sci 47:2045. doi: 10.1007/s10853-011-6005-710.1007/s10853-011-6005-7 ↗
17. Henriksen I, Våagen SR, Sande SA, Smistad G, Karlsen J (1997) Int J Pharm 146:193. doi: 10.1016/s0378-5173(96)04801-610.1016/S0378-5173(96)04801-6 ↗
18. Takeuchi H, Matsui Y, Yamamoto H, Kawashima Y (2003) J Controlled Release 86:235. doi: 10.1016/s0168-3659(02)00411-x10.1016/S0168-3659(02)00411-X ↗
19. Wang H, Zhao P, Liang X et al (2010) Biomaterials 31:4129. doi: 10.1016/j.biomaterials.2010.01.08910.1016/j.biomaterials.2010.01.089 ↗
20. Zhao P, Wang H, Yu M et al (2012) Eur J Pharm Biopharm 81:248. doi: 10.1016/j.ejpb.2012.03.00410.1016/j.ejpb.2012.03.004 ↗
21. Su W, Wang H, Wang S et al (2012) Int J Pharm 426:170. doi: 10.1016/j.ijpharm.2012.01.01310.1016/j.ijpharm.2012.01.013 ↗
22. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1996) Pharm Res 13:89610.1023/A:1016009313548 ↗
23. Kozlova NO, Bruskovskaya IB, Okuneva IB et al (2001) Biochim Biophys Acta 1514:13910.1016/S0005-2736(01)00381-9 ↗
24. Guo J, Ping Q, Jiang G, Huang L, Tong Y (2003) Int J Pharm 260:167. doi: 10.1016/s0378-5173(03)00254-010.1016/S0378-5173(03)00254-0 ↗
25. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y (1994) Chem Pharm Bull 42:195410.1248/cpb.42.1954 ↗
26. Bae YH (2009) J Controlled Release 133:2. doi: 10.1016/j.jconrel.2008.09.07410.1016/j.jconrel.2008.09.074 ↗
27. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y (2004) Int J Pharm 277:39. doi: 10.1016/j.ijpharm.2003.09.05010.1016/j.ijpharm.2003.09.050 ↗
28. Kovář M, Mrkvan T, Strohalm J et al (2003) J Controlled Release 92:315. doi: 10.1016/s0168-3659(03)00340-710.1016/S0168-3659(03)00340-7 ↗
29. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC (2008) Trends Biotechnol 26:44210.1016/j.tibtech.2008.04.006 ↗
30. Li XB, Schluesener HJ, Xu SQ (2006) Arch Immunol Ther Exp 54:17710.1007/s00005-006-0026-y ↗
31. Ke C-Y, Mathias CJ, Green MA (2003) Nucl Med Biol 30:811. doi: 10.1016/s0969-8051(03)00117-310.1016/S0969-8051(03)00117-3 ↗
32. Fujisawa T, Miyai H, Hironaka K et al (2012) Int J Pharm 436:564. doi: 10.1016/j.ijpharm.2012.07.02410.1016/j.ijpharm.2012.07.024 ↗
33. Hilgenbrink AR, Low PS (2005) J Pharm Sci 94:2135. doi: 10.1002/jps.2045710.1002/jps.20457 ↗
34. Liu S-Q, Wiradharma N, Gao S-J, Tong YW, Yang Y-Y (2007) Biomaterials 28:1423. doi: 10.1016/j.biomaterials.2006.11.01310.1016/j.biomaterials.2006.11.013 ↗
35. Lu Y, Low PS (2003) J Controlled Release 91:1710.1016/S0168-3659(03)00215-3 ↗
36. Leamon CP, Low PS (2001) Drug Discov Today 6:44. doi: 10.1016/s1359-6446(00)01594-410.1016/S1359-6446(00)01594-4 ↗
37. Sabharanjak S, Mayor S (2004) Adv Drug Deliv Rev 56:1099. doi: 10.1016/j.addr.2004.01.01010.1016/j.addr.2004.01.010 ↗
38. Zhu H, Liu F, Guo J, Xue J, Qian Z, Gu Y (2011) Carbohydr Polym 86:1118. doi: 10.1016/j.carbpol.2011.05.06110.1016/j.carbpol.2011.05.061 ↗
39. Zhao P, Wang H, Yu M et al (2010) Pharm Res 27:1914. doi: 10.1007/s11095-010-0196-510.1007/s11095-010-0196-5 ↗
40. Chen J, Li S, Shen Q (2012) Eur J Pharm Sci 47:430. doi: 10.1016/j.ejps.2012.07.00210.1016/j.ejps.2012.07.002 ↗
41. Wang F, Zhang D, Duan C et al (2011) Carbohydr Polym 84:1192. doi: 10.1016/j.carbpol.2011.01.01710.1016/j.carbpol.2011.01.017 ↗
42. Yang S-J, Lin F-H, Tsai H-M et al (2011) Biomaterials 32:2174. doi: 10.1016/j.biomaterials.2010.11.03910.1016/j.biomaterials.2010.11.039 ↗
43. Wan A, Sun Y, Li H (2008) Int J Biol Macromol 43:415. doi: 10.1016/j.ijbiomac.2008.07.01610.1016/j.ijbiomac.2008.07.016 ↗
44. Voinova MV, Galkin VL, Kosevich AM (1990) Bioelectrochem Bioenerg 24:143. doi: 10.1016/0302-4598(90)85017-c10.1016/0302-4598(90)85017-C ↗
45. Sułkowski WW, Pentak D, Nowak K, Sułkowska A (2005) J Mol Struct 744–747:737. doi: 10.1016/j.molstruc.2004.11.07510.1016/j.molstruc.2004.11.075 ↗
46. Cercek L, Cercek B, Ockey CH (1973) Biophysik 10:19510.1007/BF01190578 ↗